Management of XXXX : does the choice of proton pump inhibitor matter?

@entity1 @entity1537 @entity10042 @entity10112 @entity354
BACKGROUND: Proton pump inhibitors (PPIs) are the treatment of choice for @entity354 ( @entity354 ). The effectiveness of PPIs throughout @entity354 management, from healing to maintenance, has not been fully studied. AIM: To compare @entity1537 with @entity10042 or @entity10112 for @entity354 management using a management model. METHODS: Data from six studies comparing @entity1537 with @entity10042 or @entity10112 for healing (4-8  weeks) or maintenance of healing (6  months) of @entity354 were incorporated into hypothetical management models to determine the proportion of @entity1 in endoscopic remission after sequential healing and maintenance therapy, assuming that @entity1 received the same PPI throughout. The number needed to treat (NNT) to achieve one more @entity1 in remission with @entity1537 vs. other PPIs was estimated. The hypothetical model was validated using results from the EXPO study, which compared @entity1537 with @entity10112 for @entity354 healing and maintenance. RESULTS: Overall, @entity1537 40  mg produced higher rates of healing (life-table estimates) than @entity10042 30  mg (82.4-92.6% vs. 77.5-88.8%; p  <  0.01) or @entity10112 40  mg (95.5% vs. 92.0%; p  <  0.001) and higher rates of endoscopic and symptomatic remission at 6  months than @entity10042 (83.0-84.8% vs. 74.0-75.9%; p  <  0.001; life-table estimates) or @entity10112 (70.9% vs. 59.6%; p  <  0.0001; observed rates). In the hypothetical management model, the NNT for @entity1537 was 9 vs. @entity10042 and 8 vs. @entity10112 . The actual NNT for @entity1537 vs. @entity10112 in the EXPO study was 9 (95% confidence interval: 6; 16). CONCLUSIONS: In this management model, @entity1537 was more effective than either @entity10042 or @entity10112 for maintaining remission after sequential healing and 6  months' maintenance therapy for @entity354 .
